News Releases

Date Title
11/30/20
Summary ToggleSunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement Merger to c reate Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)- positive   lymphomas expected to begin in the first half of 2021 Leading
11/16/20
Summary ToggleSunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ended September 30, 2020.
11/09/20
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16 th , 2020 at 4:30pm Eastern Time to discuss corporate updates and financial results for the third quarter ended
10/12/20
Summary ToggleSunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32 nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.
09/03/20
Summary ToggleSunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences. Wells Fargo 2020 Virtual Healthcare Conference Date: Thursday, September 10 Time: 2:00 PM
09/02/20
Summary ToggleSunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective as of 5:00 p.m.
08/11/20
Summary ToggleSunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from operations for the three months
08/04/20
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11 th , 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended
07/29/20
Summary ToggleSunesis Announces Pricing of $12 Million Offering of Common Stock SOUTH SAN FRANCISCO, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of common stock is $0.23 .
07/28/20
Summary ToggleSunesis Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif. , July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock, in an underwritten public offering.
07/07/20
Summary ToggleSunesis Pharmaceuticals Provides Corporate Update Company reduces workforce to focus on development of PDK1 inhibitor, SNS-510 SOUTH SAN FRANCISCO, Calif. , July 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus on development of its
06/23/20
Summary ToggleSunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program Company Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510 SOUTH SAN FRANCISCO, Calif. , June 23, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib into the
05/07/20
Summary ToggleSunesis Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2020. Loss from operations for the three months
04/30/20
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on May 7th to Discuss First Quarter 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, May 7 th , 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended
03/10/20
Summary ToggleSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif. , March 10, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals , Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2019.
03/03/20
Summary ToggleSunesis Pharmaceuticals to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, March 10, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year
02/25/20
Summary ToggleSunesis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn , Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 40th Annual Cowen Health Care